EZH2 and epithelioid sarcoma: On the therapeutic front, there has been important progress: in a pivotal phase II trial, the EZH2 inhibitor tazemetostat demonstrated clinical activity in patients with advanced or metastatic epithelioid sarcoma, showing an objective response rate of around 15% and a manageable safety profile [23].